Agenus (NASDAQ:AGEN) Stock Price Passes Above 200 Day Moving Average – Here’s Why

Agenus Inc. (NASDAQ:AGEN) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.26 and traded as high as $4.60. Agenus shares last traded at $4.42, with a volume of 922,470 shares changing hands.

Analyst Ratings Changes

AGEN has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating on shares of Agenus in a report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Agenus in a report on Wednesday, October 8th. Zacks Research upgraded Agenus to a “hold” rating in a report on Tuesday, August 12th. Finally, Wall Street Zen downgraded Agenus from a “buy” rating to a “hold” rating in a report on Sunday, August 17th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Agenus currently has a consensus rating of “Hold” and an average target price of $14.50.

Agenus Stock Performance

The stock has a fifty day simple moving average of $4.32 and a two-hundred day simple moving average of $4.26. The stock has a market capitalization of $140.82 million, a price-to-earnings ratio of -0.62 and a beta of 1.43.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.22). The firm had revenue of $25.70 million for the quarter, compared to the consensus estimate of $49.71 million. Research analysts forecast that Agenus Inc. will post -12.55 earnings per share for the current year.

Hedge Funds Weigh In On Agenus

A number of institutional investors and hedge funds have recently made changes to their positions in AGEN. Apollon Wealth Management LLC raised its holdings in shares of Agenus by 25.0% in the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 5,000 shares during the period. Catalyst Funds Management Pty Ltd bought a new stake in shares of Agenus in the 2nd quarter worth approximately $50,000. Jump Financial LLC bought a new stake in shares of Agenus in the 2nd quarter worth approximately $55,000. CWM LLC raised its holdings in shares of Agenus by 105.8% in the 2nd quarter. CWM LLC now owns 26,246 shares of the biotechnology company’s stock worth $120,000 after purchasing an additional 13,494 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Agenus by 32.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 63,685 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 15,731 shares during the period. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.